Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01546324 · ClinicalTrials.gov registry record
Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing
A clinical trial, sponsored by Natera.
- Completed
- Registry status
- 16
- Enrollment target
NCT01546324: Completed study, sponsored by Natera.
NCT01546324 is a clinical trial that has completed, run by Natera. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01546324 has completed, sponsored by Natera.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to collect blood samples from pregnant women who achieved pregnancy following in-vitro fertilization (IVF) with Natera's preimplantation aneuploidy screening (with or without single gene gene testing). These samples will be used for test development of non-invasive prenatal diagnostic testing.
Interventions
- PROCEDURE Blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2012-02 |
| Est. Completion | 2013-08 |
What the finished NCT01546324 record still lists
NCT01546324 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 16 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood draw is the first listed.
NCT01546324 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01546324 about?
NCT01546324 is a clinical study titled "Collection of Maternal Blood Samples for Development of Non-invasive Prenatal Diagnostic Testing". The purpose of this study is to collect blood samples from pregnant women who achieved pregnancy following in-vitro fertilization (IVF) with Natera's preimplantation aneuploidy screening (with or without single gene gene testing). These samples will be used for test development of non-invasive prena...
What is the current status of trial NCT01546324?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2012-02. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01546324?
The interventions under investigation include: Blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT01546324?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia